- Condition: Alzheimer's Disease
Interventions: Drug: LY2886721; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Alzheimer´s Disease
Interventions: Biological: Immune Globulin Intravenous (Human), 10% Solution; Biological: Human albumin 0.25%
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2012 - Condition: Mild Cognitive Impairment
Interventions: Drug: Atomoxetine; Drug: Placebo
Sponsors: Emory University; Emory University; National Institute on Aging (NIA)
Not yet recruiting - verified March 2012 - Condition: Alzheimer's Disease
Interventions: Drug: BMS-241027; Drug: BMS-241027; Drug: BMS-241027; Drug: Placebo matching BMS-241027
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Alzheimer's Disease
Interventions: Drug: MABT5102A; Drug: MABT5102A; Drug: placebo; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified August 2011 - Condition: Alzheimer's Disease
Interventions: Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812)
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified May 2012 - Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified May 2012 - Condition: Alzheimer's Disease
Interventions: Drug: Active Comparator: A; Drug: Placebo Comparator B; Drug: Active Comparator B; Drug: Placebo Comparator A
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified January 2012 - Condition: Alzheimer's Disease
Interventions: Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Other: Placebo
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified May 2012 - Condition: Health Promotion
Interventions: Behavioral: Usual Care; Behavioral: Psycho-education; Behavioral: Psycho-education plus physical exercise
Sponsors: Emory University; Emory University; National Institute of Nursing Research (NINR)
Recruiting - verified May 2012 - Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified February 2012 - Condition: Alzheimer Disease
Intervention: Drug: Bapineuzumab 0.5 mg/kg
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Alzheimer Disease
Intervention: Drug: bapineuzumab
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified March 2012 - Condition: Alzheimer's Disease
Interventions: Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF; Procedure: Placebo Surgery
Sponsors: Ceregene; Ceregene; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified May 2012 - Conditions: Mild Cognitive Impairment; Alzheimer's Disease; Traumatic Brain Injury
Interventions: Behavioral: explicit memory training; Behavioral: implicit memory training
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Emory University
Recruiting - verified May 2012 - Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: bapineuzumab; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
 |
Join Clinical Trials in Georgia for Alzheimers Disease |
